Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice

Tohoku Journal of Experimental Medicine

Volumn 228, Issue 4, 2012, Pages 305-315

  Noda, Kazuki ^a   Hosoya, Maki ^a   Nakajima, Sota ^a   Ohashi, Junko ^a   Fukumoto, Yoshihiro ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor blocker; Atherosclerosis; Calcium channel blocker; Combination therapy; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AZELNIDIPINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDRALAZINE; OLMESARTAN; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIATHEROGENIC ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; CELL INFILTRATION; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG ACTIVITY; ENZYME ACTIVATION; HYPERLIPOPROTEINEMIA TYPE 3; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; UPREGULATION; VASCULAR FIBROSIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, THORACIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; AZETIDINECARBOXYLIC ACID; AZO COMPOUNDS; BLOOD PRESSURE; BODY WEIGHT; CALCIUM CHANNEL BLOCKERS; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; IMIDAZOLES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MYOCYTES, CARDIAC; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHOSPHORYLATION; SYSTOLE; TETRAZOLES;

EID: 84869052334     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.228.305     Document Type: Article

References (53)

1. Abe, M., Maruyama, N., Okada, K., Matsumoto, S., Matsumoto, K. & Soma, M. (2011) Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens. Res., 34, 935-941.
2. Bauer, P.M., Fulton, D., Boo, Y.C., Sorescu, G.P., Kemp, B.E., Jo, H. & Sessa, W.C. (2003) Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase. J. Biol. Chem., 278, 14841-14849.
3. Charo, I.F. & Taubman, M.B. (2004) Chemokines in the pathogenesis of vascular disease. Circ. Res., 95, 858-866.
4. Dudzinski, D.M. & Michel, T. (2007) Life history of eNOS: partners and pathways. Cardiovasc. Res., 75, 247-260.
5. Fliser, D., Buchholz, K. & Haller, H. (2004) Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation, 110, 1103-1107.
6. Fujita, M., Okuda, H., Tsukamoto, O., Asano, Y., Hirata, Y.L., Kim, J., Miyatsuka, T., Takashima, S., Minamino, T., Tomoike, H. & Kitakaze, M. (2006) Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler. Thromb. Vasc. Biol., 26, e138-e142.
7. Gandhi, S., Srinivasan, B.P. & Akarte, A.S. (2012) Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats. Euro. J. Pharm. Sci., 46, 32-42.
8. Honda, H., Hosaka, N., Aoshima, Y., Hirai, Y., Michihata, T. & Akizawa, T. (2012) Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)carboxymethyl-lysine levels in hemodialysis patients. Clin. Exp. Hypertens., 34, 17-23.
9. Hosoya, M., Ohashi, J., Sawada, A., Takaki, A. & Shimokawa, H. (2010) Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice. Circ. J, 74, 798-806.
10. How, O.J., Aasum, E., Severson, D.L., Chan, W.Y., Essop, M.F. & Larsen, T.S. (2006) Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes, 55, 466-473.
11. Inaba, S., Iwai, M., Tomono, Y., Senba, I., Furuno, M., Kanno, H., Okayama, H., Mogi, M., Higaki, J. & Horiuchi, M. (2009) Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. Am. J. Hypertens., 22, 145-150.
12. Iwanaga, Y. & Miyazaki, S. (2010) Heart failure, chronic kidney disease, and biomarkers-an integrated viewpoint-. Circ. J., 74, 1274-1282.
13. Jinno, T., Iwai, M., Li, Z., Li, J.M., Liu, H.W., Cui, T.X., Rakugi, H., Ogihara, T. & Horiuchi, M. (2004) Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension, 43, 263-269.
14. Kandler, M.R., Mah, G.T., Tejani, A.M., Stabler, S.N. & Salzwedel, D.M. (2011) Hydralazine for essential hypertension. Cochrane Database Syst Rev, CD004934.
15. Kawashima, S. & Yokoyama, M. (2004) Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 24, 998-1005.
16. Kennedy, J.M. & Zochodne, D.W. (2000) The regenerative deficit of peripheral nerves in experimental diabetes: its extent, timing and possible mechanisms. Brain, 123, 2118-2129.
17. Knock, G.A. & Ward, J.P. (2011) Redox regulation of protein kinases as a modulator of vascular function. Antioxid. Redox Signal., 15, 1531-1547.
18. Kojima, T., Miyauchi, K., Yokoyama, T., Yokoyama, K., Kurata, T., Suwa, S., Kawamura, M., Tamura, H., Okazaki, S., Inoue, K., Fujiwara, Y., Sumiyoshi, M., Tanimoto, K., Nakazato, Y., Yamagami, S., Hiro, T., Komiyama, N. & Daida, H. (2011) Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). Circ. J, 75, 1071-1079.
19. Kuramoto, K., Ichikawa, S., Hirai, A., Kanada, S., Nakachi, T. & Ogihara, T. (2003) Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens. Res., 26, 201-208.
20. Lerman, L.O., Textor, S.C. & Grande, J.P. (2009) Mechanisms of tissue injury in renal artery stenosis: ischemia and beyond. Prog. Cardiovasc. Dis., 52, 196-203.
21. Libby, P., Okamoto, Y., Rocha, V.Z. & Folco, E. (2010) Inflammation in atherosclerosis: transition from theory to practice. Circ. J., 74, 213-220.
22. Lumeng, C.N., Bodzin, J.L. & Saltiel, A.R. (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest., 117, 175-184.
23. Luscher, T.F., Pieper, M., Tendera, M., Vrolix, M., Rutsch, W., van den Branden, F., Gil, R., Bischoff, K.O., Haude, M., Fischer, D., Meinertz, T. & Munzel, T. (2009) A randomized placebocontrolled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart 1, 30, 1590-1597.
24. Matsui, T., Yamagishi, S., Takeuchi, M., Ueda, S., Fukami, K. & Okuda, S. (2009) Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptorgamma activation. Biochem. Biophys. Res. Commun., 385, 269-272.
25. Matsui, T., Yamagishi, S., Takeuchi, M., Ueda, S., Fukami, K. & Okuda, S. (2010) Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferatoractivated receptor-gamma activation. Biochem. Biophys. Res. Commun., 398, 326-330.
26. Matsui, T., Yamagishi, S., Ueda, S., Nakamura, K., Imaizumi, T., Takeuchi, M. & Inoue, H. (2007) Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation endproduct (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J. Int. Med. Res., 35, 482-489.
27. Ming, X.F., Viswambharan, H., Barandier, C., Ruffieux, J., Kaibuchi, K., Ruconi, S. & Yang, Z. (2002) Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol. Cell. Biol., 22, 8467-8477.
28. Mire, D.E., Silfani, T.N. & Pugsley, M.K. (2005) A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J. Cardiovasc. Pharmacol., 46, 585-593.
29. Morikawa, K., Matoba, T., Kubota, H., Hatanaka, M., Fujiki, T., Takahashi, S., Takeshita, A. & Shimokawa, H. (2005) Influence of diabetes mellitus, hypercholesterolemia, and their combination on EDHF-mediated responses in mice. J. Cardiovasc. Pharmacol., 45, 485-490.
30. Nakajima, S., Ohashi, J., Sawada, A., Noda, K., Fukumoto, Y. & Shimokawa, H. (2012) Essential role of bone marrow for microvascular endothelial and metabolic functions in mice. Circ. Res., 111, 87-96.
31. Nakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Koide, H., Ueda, Y., Takeuchi, M. & Yamagishi, S. (2011) Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease. Clin. Cardiol., 34, 372-377.
32. Nakano, K., Egashira, K., Ohtani, K., Gang, Z., Iwata, E., Miyagawa, M. & Sunagawa, K. (2008) Azelnidipine has antiatherosclerotic effects independent of its blood pressurelowering actions in monkeys and mice. Atherosclerosis, 196, 172-179.
33. Nakano, M., Fukumoto, Y., Satoh, K., Ito, Y., Kagaya, Y., Ishii, N., Sugamura, K. & Shimokawa, H. (2010) OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization. Cardiovasc. Res., 88, 539-546.
34. Nangaku, M., Miyata, T., Sada, T., Mizuno, M., Inagi, R., Ueda, Y., Ishikawa, N., Yuzawa, H., Koike, H., van Ypersele de Strihou, C. & Kurokawa, K. (2003) Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J. Am. Soc. Nephrol., 14, 1212-1222.
35. Ohashi, J., Sawada, A., Nakajima, S., Noda, K., Takaki, A. & Shimokawa, H. (2012) Mechanisms for enhanced endothelium-derived hyperpolarizing factor-mediated responses in microvessels in mice. Circ. J, 76, 1768-1779.
36. Rashid, M., Tawara, S., Fukumoto, Y., Seto, M., Yano, K. & Shimokawa, H. (2009) Importance of Rac l signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ. J., 73, 361-370.
37. Ricardo, S.D., van Goor, H. & Eddy, A.A. (2008) Macrophage diversity in renal injury and repair. J. Clin. Invest., 118, 3522-3530.
38. Schmidt, A.M., Yan, S.D., Wautier, J.L. & Stern, D. (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res., 84, 489-497.
39. Shimokawa, H. (1999) Primary endothelial dysfunction: atherosclerosis. I Mol. Cell. Cardiol., 31, 23-37.
40. Sukumaran, V., Watanabe, K., Veeraveedu, P.T., Gurusamy, N., Ma, M., Thandavarayan, R.A., Lakshmanan, A.P., Yamaguchi, K., Suzuki, K. & Kodama, M. (2011) Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis. Int. J. Biol. Sci., 7. 154-167.
41. Suzuki, J., Iwai, M., Li, Z., Li, J.M., Min, L.J., Ide, A., Yoshii, T., Oshita, A., Mogi, M. & Horiuchi, M. (2005) Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J. Hypertens., 23, 1383-1389.
42. Takaki, A., Morikawa, K., Tsutsui, M., Murayama, Y., Tekes, E., Yamagishi, H., Ohashi, J., Yada, T., Yanagihara, N. & Shimokawa, H. (2008) Crucial role of nitric oxide synthases system in endothelium-dependent hyperpolarization in mice. I Exp. Med., 205, 2053-2063.
43. Tanaka, N., Yonekura, H., Yamagishi, S., Fujimori, H., Yamamoto, Y. & Yamamoto, H. (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factorkappaB, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem., 275, 25781-25790.
44. Tsoporis, J.N., Izhar, S., Leong-Poi, H., Desjardins, J.F., Huttunen, H.J. & Parker, T.G. (2010) S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction. Circ. Res., 106, 93-101.
45. Tsuda, M., Iwai, M., Li, J.M., Li, H.S., Min, L.J., Ide, A., Okumura, M., Suzuki, J., Mogi, M., Suzuki, H. & Horiuchi, M. (2005) Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension, 45, 545-551.
46. Vanhoutte, P.M. (2009) Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ. 1, 73, 595-601.
47. Wang, W., Kagaya, Y., Asaumi, Y., Fukui, S., Takeda, M. & Shimokawa, H. (2011) Protective effects of recombinant human erythropoietin against pressure overload-induced left ventricular remodeling and premature death in mice. Tohoku. J. Exp. Med., 225, 131-143.
48. Wautier, M.P., Chappey, O., Corda, S., Stern, D.M., Schmidt, A.M. & Wautier, J.L. (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab., 280, E685-E694.
49. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L. & Ferrante, A.W. Jr. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 112, 1796-1808.
50. Yagi, S., Akaike, M., Aihara, K., Ishikawa, K., Iwase, T., Ikeda, Y., Soeki, T., Yoshida, S., Sumitomo-Ueda, Y., Matsumoto, T. & Sata, M. (2010) Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury. Hypertension, 55, 918-923.
51. Yamagishi, S., Matsui, T., Nakamura, K., Inoue, H., Takeuchi, M., Ueda, S., Fukami, K., Okuda, S. & Imaizumi, T. (2008) Olmesartan blocks advanced glycation end products (AGEs)induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc. Res., 75, 130-134.
52. Yamamoto, E., Dong, Y.F., Kataoka, K., Yamashita, T., Tokutomi, Y., Matsuba, S., Ichijo, H., Ogawa, H. & Kim-Mitsuyama, S. (2008) Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension, 52, 573-580.
53. Yoshida, T., Yamagishi, S., Nakamura, K., Matsui, T., Imaizumi, T., Takeuchi, M., Koga, H., Ueno, T. & Sata, M. (2006) Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia, 49, 3094-3099.